X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus disease in high-risk adult kidney transplant recipients.
Lead Product(s): Letermovir,Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2024
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.
Lead Product(s): Letermovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.
Lead Product(s): Letermovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex.
Lead Product(s): Letermovir,Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
In analysis of studies, compared to controls, primary prophylaxis with PREVYMIS was associated at 100 days of follow-up after alloHCT with: 87% lower odds of CMV reactivation; 91% lower odds for clinically significant CMV infection, 69% lower odds of CMV disease.
Lead Product(s): Letermovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
PREVYMIS is a first-in-class antiviral agent that was approved by the U.S. Food and Drug Administration in 2017 and is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Lead Product(s): Letermovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high risk for CMV reactivation.
Lead Product(s): Letermovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $220.0 million Upfront Cash: $220.0 million
Deal Type: Acquisition June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
